ESR2 and breast carcinoma: Treatment with DPN significantly potentiated the effect of cisplatin on p53-dependent gene transcription (Figure 3C), indicating a synergism between ERβ and p53 that may account for some of their previously observed anti-tumor effects in breast cancer [31, 37].